Genfit SANASDAQ:GNFT
- LAST PRICE4.2400
- TODAY'S CHANGE (%)-0.0700 (-1.6241%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close4.2400 / 4.3100
- Day Range
- 52 Week Range
- Volume705
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GNFT |
|---|---|---|
| 10:51 ET | 100 | 4.24 |
Nov 13, 2024
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting(R) 2024, from 4:10PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:10PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 7, 2024
GENFIT Reports Third Quarter 2024 Financial Information, from 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Genfit SA | 211.9M | -7.0x | --- |
Mersana Therapeutics Inc | 242.9M | -3.2x | --- |
Caribou Biosciences Inc | 179.3M | -1.2x | --- |
Nanobiotix SA | 176.8M | -3.3x | --- |
Artiva Biotherapeutics Inc | 264.1M | 0.0x | --- |
MacroGenics Inc | 201.5M | -2.0x | --- |
Company Information
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Contact Information
- Headquarters
- Parc Eurasante 885 avenue Eugene AvineeLOOS, France 59120
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Jean-Francois Mouney
- Chief Executive Officer
- Pascal Prigent
- Independent Vice Chairman of the Board
- Eric Baclet
- Chief Financial Officer
- Thomas Baetz
- Chief Operating Officer
- Pascal Caisey
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $211.9M |
|---|---|
Revenue (TTM) | $40.0M |
Shares Outstanding | 50.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.20 |
EPS | $-0.61 |
Book Value | $1.43 |
P/E Ratio | -7.0x |
Price/Sales (TTM) | 5.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -69.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
